Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00238446 | Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients | PHASE3 | COMPLETED | - | — | — | Apr 1, 2003 | - | Feb 24, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| EC-MPS | DRUG | - |
Inclusion Criteria: Patients who were participating in the core study CERL080A2401 and have successfully completed the first 12 months of the core study Exclusion Criteria: Patients who did not complete the 12-month core study CERL080A2401 Other protocol-defined inclusion/exclusion criteria may ...